WR-6026

Known as: WR-006026, WR6026, WR 6026 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1983-2008
012319832008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Sitamaquine (WR6026), an 8-aminoquinoline derivative, is a new antileishmanial oral drug. As a lipophilic weak base, it rapidly… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
Sitamaquine (WR6026) is an 8-aminoquinoline in development for the oral treatment of visceral leishmaniasis (VL). This was an… (More)
Is this relevant?
2001
2001
There are no recognized orally administered treatments for any of the leishmaniases. The 8-aminoquinoline WR6026 is an orally… (More)
Is this relevant?
2000
2000
Acidocalcisomes are acidic vacuoles present in trypanosomatids that contain most of the cellular calcium. The data presented here… (More)
Is this relevant?
1997
1997
Currently available primary screens for selection of candidate antileishmanial compounds are not ideal. The choices include… (More)
Is this relevant?
1997
1997
The presently used therapy for Babesia microti infections, a combination of quinine and clindamycin, does not always result in… (More)
Is this relevant?
1994
1994
The efficacy of an oral 8-aminoquinoline (8-[[6-(diethylamino)hexyl]amino]-6-methoxy-4-methylquinoline) (WR6026) in the treatment… (More)
Is this relevant?
1992
1992
The use of low concentrations of digitonin allowed the quantitative determination of the mitochondrial membrane potential of… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
1991
1991
The pharmacokinetics of the anti-leishmanial agent WR 6026 (8-(6-diethylaminohexylamino)-6-methoxy-4-methylquinoline… (More)
Is this relevant?
1991
1991
Three 8-aminoquinolines from the Walter Reed Army Institute for Research (WRAIR), WR6026, WR238605, and WR242511, strongly… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?